Comparative Pharmacology
Head-to-head clinical analysis: SIMLIYA versus ZOVIA 1 35E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SIMLIYA versus ZOVIA 1 35E 21.
SIMLIYA vs ZOVIA 1/35E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not available; SIMLIYA is a trademarked combination drug with no established mechanism of action.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibits ovulation, alters cervical mucus and endometrial lining.
Insulin glargine (SIMLIYA) is a long-acting insulin analog administered subcutaneously once daily. Typical starting dose for adults with type 2 diabetes is 0.2 units/kg or 10 units once daily, adjusted based on blood glucose targets. For type 1 diabetes, total daily dose is divided; basal insulin glargine typically constitutes 40-50% of total daily dose, given once daily.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets (if included in the pack) or a 7-day pill-free interval. Each tablet contains ethinyl estradiol 0.035 mg and norethindrone 1 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours; clinically, steady state is achieved within 2-3 days of regular dosing.
Norethindrone: 5-12 hours (terminal elimination half-life, approximately 8 hours). Ethinyl estradiol: biphasic with terminal half-life of 10-20 hours (mean 15 hours). Clinical context: Steady state reached in 5-7 days.
Renal excretion of unchanged drug accounts for ~70% of elimination; biliary/fecal excretion accounts for ~25%, with the remainder as metabolites.
Renal (approximately 40% as parent drug and metabolites; 20-40% as metabolites; 15-20% as unchanged drug), fecal (30-50% via bile as metabolites), and less than 2% in breast milk.
Category C
Category C
Oral Contraceptive
Oral Contraceptive